- Home
- HDL vs ORIC Comparison
HDL vs ORIC Comparison
Compare HDL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HDL | ORIC |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.1M | 861.3M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HDL | ORIC |
|---|---|---|
| Price | $14.00 | $14.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | 918.0 | ★ 1.5M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $12.94 | N/A |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.00 | $7.23 |
| 52 Week High | $20.35 | $14.93 |
Technical Indicators
Market Signals| Indicator | HDL | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.22 | 58.75 |
| Support Level | $13.07 | $13.12 |
| Resistance Level | $15.40 | $13.97 |
| Average True Range (ATR) | 0.12 | 0.63 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 83.33 | 52.96 |
Price Performance
Historical ComparisonAbout HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.